vorinostat + bortezomib + dexamethasone

Vorinostat + bortezomib + dexamethasone is a combination regimen investigated primarily for the treatment of relapsed or refractory multiple myeloma. Vorinostat is a histone deacetylase (HDAC) inhibitor that blocks HDAC enzymes involved in chromatin remodeling and gene expression regulation. Bortezomib is a proteasome inhibitor that disrupts protein degradation pathways in cancer cells. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. The combination leverages the synergistic effects of HDAC inhibition and proteasome inhibition to induce apoptosis in myeloma cells while dexamethasone enhances anti-myeloma activity and reduces inflammation[1][3][7]. Clinical trials have shown this regimen can achieve high response rates but may be limited by toxicity; it remains under investigation for optimizing efficacy and tolerability[1][4].

Other names

SAHAPS-341PS341PS 341adrenocorticosteroid